Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NSC319726 |
Synonyms | |
Therapy Description |
NSC319726 restores wild-type conformation to mutant Tp53, resulting in reactivation of Tp53 signaling in Tp53-mutant cells, and potentially leading to increased tumor cell death (PMID: 22624712, PMID: 26719703). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NSC319726 | NSC-319726|NSC 319726 | p53 Activator 11 | NSC319726 restores wild-type conformation to mutant Tp53, resulting in reactivation of Tp53 signaling in Tp53-mutant cells, and potentially leading to increased tumor cell death (PMID: 22624712, PMID: 26719703). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 R175H | breast cancer | sensitive | NSC319726 | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712). | 22624712 |
TP53 R273W | breast cancer | resistant | NSC319726 | Preclinical - Cell culture | Actionable | In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of breast cancer harboring TP53 R273W (PMID: 22624712). | 22624712 |
TP53 R175L | lung large cell carcinoma | sensitive | NSC319726 | Preclinical - Cell culture | Actionable | In a preclinical study, lung large cell carcinoma cells harboring TP53 R175L demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712). | 22624712 |
TP53 wild-type | lung large cell carcinoma | resistant | NSC319726 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of TP53 wild-type lung large cell carcinoma (PMID: 22624712). | 22624712 |
TP53 R175H | ovarian cancer | sensitive | NSC319726 | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726-induced growth inhibition in culture and in cell line xenograft models (PMID: 22624712). | 22624712 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|